BRPI9712917B8 - composição de vacina compreendendo toxóides diftérico, tetânico e pertussis. - Google Patents

composição de vacina compreendendo toxóides diftérico, tetânico e pertussis.

Info

Publication number
BRPI9712917B8
BRPI9712917B8 BRPI9712917A BRPI9712917A BRPI9712917B8 BR PI9712917 B8 BRPI9712917 B8 BR PI9712917B8 BR PI9712917 A BRPI9712917 A BR PI9712917A BR PI9712917 A BRPI9712917 A BR PI9712917A BR PI9712917 B8 BRPI9712917 B8 BR PI9712917B8
Authority
BR
Brazil
Prior art keywords
diphtheria
tetanus
pertussis
vaccine composition
vaccine
Prior art date
Application number
BRPI9712917A
Other languages
English (en)
Inventor
Vandecasserie Cristian
Stephenne Jean
Florent Patrick
Original Assignee
Glaxosmithkline Biologicals Sa
Smithkline Beecham Biologicals S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa, Smithkline Beecham Biologicals S A filed Critical Glaxosmithkline Biologicals Sa
Publication of BRPI9712917B1 publication Critical patent/BRPI9712917B1/pt
Publication of BRPI9712917B8 publication Critical patent/BRPI9712917B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

patente de invenção:<b>"vacina pertussis acelular com toxóides diftérico e tetânico"<d>. a invenção fornece uma vacina contra difteria, tétano e pertussis compreendendo uma baixa dose de cada dos toxóide diftérico (d), toxóide tetânico (t), toxina pertussis (pt), hemaglutinina filamentosa (fha) e pertactin (69k). a vacina mantém uma capacidade de prevenir pertussis ao mesmo tempo que apresentando reatogenicidade excepcionalmente baixa. também são fornecidas combinações de vacinas compreendendo antígenos adicionais.
BRPI9712917A 1996-11-07 1997-11-04 composição de vacina compreendendo toxóides diftérico, tetânico e pertussis. BRPI9712917B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9623233.5A GB9623233D0 (en) 1996-11-07 1996-11-07 Vaccine composition
PCT/EP1997/006180 WO1998019702A1 (en) 1996-11-07 1997-11-04 Acellular pertussis vaccine with diphthriae- and tetanus-toxoids

Publications (2)

Publication Number Publication Date
BRPI9712917B1 BRPI9712917B1 (pt) 2019-12-03
BRPI9712917B8 true BRPI9712917B8 (pt) 2021-05-25

Family

ID=10802615

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI9712917A BRPI9712917B8 (pt) 1996-11-07 1997-11-04 composição de vacina compreendendo toxóides diftérico, tetânico e pertussis.
BR9712917-8A BR9712917A (pt) 1996-11-07 1997-11-04 Vacina pertussis acelular com toxóides diftérico e tetânico

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR9712917-8A BR9712917A (pt) 1996-11-07 1997-11-04 Vacina pertussis acelular com toxóides diftérico e tetânico

Country Status (30)

Country Link
EP (2) EP0941117B1 (pt)
JP (1) JP3980652B2 (pt)
KR (1) KR100518044B1 (pt)
CN (1) CN1130226C (pt)
AR (1) AR011509A1 (pt)
AT (2) ATE295178T1 (pt)
AU (1) AU710475B2 (pt)
BR (2) BRPI9712917B8 (pt)
CA (1) CA2271008C (pt)
CO (1) CO4910171A1 (pt)
CY (2) CY2407B1 (pt)
CZ (1) CZ295954B6 (pt)
DE (3) DE69733285T3 (pt)
DK (2) DK1240905T5 (pt)
ES (2) ES2240647T7 (pt)
GB (1) GB9623233D0 (pt)
HK (1) HK1050473B (pt)
HU (1) HU224126B1 (pt)
IL (1) IL129530A (pt)
LU (1) LU91183I2 (pt)
NO (2) NO320186B1 (pt)
NZ (1) NZ335384A (pt)
PL (1) PL188460B1 (pt)
PT (2) PT941117E (pt)
SA (1) SA98181128B1 (pt)
SI (2) SI1240905T1 (pt)
TR (1) TR199900979T2 (pt)
TW (1) TW471971B (pt)
WO (1) WO1998019702A1 (pt)
ZA (1) ZA979984B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1004314A1 (fr) * 1998-11-26 2000-05-31 Pasteur Merieux MSD Vaccin T.d. Polio rappel pour une population vaccinée ou sensibilisée
KR100374813B1 (ko) * 2000-04-07 2003-03-03 녹십자백신 주식회사 디프테리아, 파상풍 톡소이드, 정제백일해 및비형간염표면항원을 포함한 4가 혼합백신 및 그 제조 방법
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
KR100401423B1 (ko) * 2001-01-10 2003-10-17 주식회사 엘지생명과학 혼합 백신의 제조 방법
JP5007425B2 (ja) * 2006-01-30 2012-08-22 財団法人ヒューマンサイエンス振興財団 百日咳ワクチンの安全性評価方法
GB0616306D0 (en) * 2006-08-16 2006-09-27 Novartis Ag Vaccines
GB0822633D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Formulation
ES2443952T3 (es) 2009-09-02 2014-02-21 Novartis Ag Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
ES2458355T3 (es) 2010-09-01 2014-05-05 Novartis Ag Adsorción de inmunopotenciadores sobre sales metálicas insolubles
WO2012117377A1 (en) 2011-03-02 2012-09-07 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
CN102363041A (zh) * 2011-11-17 2012-02-29 成都欧林生物科技股份有限公司 不含防腐剂疫苗的制作工艺
MX372965B (es) 2012-03-08 2020-04-01 Glaxosmithkline Biologicals Sa Formulaciones adyuvadas de vacunas de difteria, tetanos y tos ferina (dtp) de refuerzo.
CN102793915B (zh) * 2012-07-25 2013-10-23 天津康希诺生物技术有限公司 一种无细胞百日咳疫苗的生产方法
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
WO2014024026A1 (en) 2012-08-06 2014-02-13 Glaxosmithkline Biologicals S.A. Method for eliciting in infants an immune response against rsv and b. pertussis
CN103100081A (zh) * 2012-12-26 2013-05-15 天津康希诺生物技术有限公司 一种多价联合疫苗
AP2015008702A0 (en) 2013-03-08 2015-09-30 Crucell Holland Bv Acellular pertussis vaccine
AU2014304545A1 (en) 2013-08-05 2016-02-25 Glaxosmithkline Biologicals S.A. Combination immunogenic compositions
CN114748616A (zh) * 2022-05-23 2022-07-15 中国医学科学院医学生物学研究所 一种成人青少年用无细胞百白破联合疫苗及其制备方法
CN117417419B (zh) * 2023-01-10 2024-04-19 康希诺生物股份公司 一种百日咳毒素脱毒方法及无细胞百白破联合疫苗
CN119524117B (zh) * 2025-01-23 2025-09-23 康希诺生物股份公司 免疫原性组合物、百白破联合疫苗及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI861417A0 (fi) 1985-04-15 1986-04-01 Endotronics Inc Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
US4895800A (en) 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
AP56A (en) 1987-01-30 1989-09-26 Smithkline Biologicals S A Hepatitis B virus surface antigens and hybrid antigehs containing them.
EP1088830A3 (en) 1987-06-22 2004-04-07 Medeva Holdings B.V. Hepatitis b surface antigen particles
ES2056799T3 (es) 1987-07-17 1994-10-16 Rhein Biotech Ges Fur Biotechn Moleculas de adn codante para las regiones de control fmdh y gen estructural para una proteina que tiene una actividad de fmdh y su uso.
DK0414374T3 (da) 1989-07-25 1998-03-09 Smithkline Beecham Biolog Hidtil ukendte antigener og fremgangsmåder til fremstilling deraf
GB9007024D0 (en) 1990-03-29 1990-05-30 Imperial College Novel vaccine
FI945483A7 (fi) * 1992-05-23 1995-01-20 Smithkline Beecham Biologicals S A Hepatiitti B - pinta-antigeenejä ja muita antigeenejä sisältäviä yhdistelmärokotteita

Also Published As

Publication number Publication date
CA2271008A1 (en) 1998-05-14
HU224126B1 (hu) 2005-05-30
CY2407B1 (en) 2004-09-10
NO2006005I2 (no) 2010-04-12
NZ335384A (en) 2000-10-27
AR011509A1 (es) 2000-08-30
ATE222773T1 (de) 2002-09-15
PT941117E (pt) 2002-12-31
EP0941117A1 (en) 1999-09-15
TW471971B (en) 2002-01-11
BRPI9712917B1 (pt) 2019-12-03
ZA979984B (en) 1998-07-23
PL188460B1 (pl) 2005-02-28
PT1240905E (pt) 2005-09-30
CN1130226C (zh) 2003-12-10
SA98181128B1 (ar) 2006-03-25
DE69733285T3 (de) 2010-03-25
EP1240905B3 (en) 2009-08-26
NO992156L (no) 1999-05-04
AU710475B2 (en) 1999-09-23
NO320186B1 (no) 2005-11-07
CN1236321A (zh) 1999-11-24
HK1050473A1 (en) 2003-06-27
EP1240905A1 (en) 2002-09-18
HUP9904287A1 (hu) 2000-04-28
ES2240647T7 (es) 2010-03-31
CY2568B1 (en) 2008-07-02
DK1240905T5 (da) 2010-01-11
ATE295178T1 (de) 2005-05-15
CZ295954B6 (cs) 2005-12-14
BR9712917A (pt) 1999-12-07
CO4910171A1 (es) 2000-04-24
DE69733285T2 (de) 2006-01-12
DE69715031T2 (de) 2003-05-08
SI0941117T1 (en) 2002-12-31
IL129530A (en) 2005-11-20
ES2182131T3 (es) 2003-03-01
EP1240905B1 (en) 2005-05-11
HK1050473B (en) 2006-03-03
KR20000053092A (ko) 2000-08-25
DK0941117T3 (da) 2002-11-18
PL333127A1 (en) 1999-11-22
NO2006005I1 (no) 2006-05-08
LU91183I2 (fr) 2005-09-20
JP3980652B2 (ja) 2007-09-26
CZ164099A3 (cs) 1999-10-13
EP0941117B1 (en) 2002-08-28
DE69715031D1 (de) 2002-10-02
KR100518044B1 (ko) 2005-09-30
HUP9904287A3 (en) 2001-05-28
IL129530A0 (en) 2000-02-29
GB9623233D0 (en) 1997-01-08
DE69733285D1 (de) 2005-06-16
ES2240647T3 (es) 2005-10-16
SI1240905T1 (en) 2005-10-31
DK1240905T3 (da) 2005-07-18
WO1998019702A1 (en) 1998-05-14
CA2271008C (en) 2008-07-22
HK1022638A1 (en) 2000-08-18
NO992156D0 (no) 1999-05-04
DE122005000046I1 (de) 2005-12-29
AU5319698A (en) 1998-05-29
JP2001503422A (ja) 2001-03-13
TR199900979T2 (xx) 1999-07-21

Similar Documents

Publication Publication Date Title
BRPI9712917B8 (pt) composição de vacina compreendendo toxóides diftérico, tetânico e pertussis.
LU91596I2 (fr) Combinaison d&#39;anatoxine diphtérique, d&#39;anatoxine tétanique,d&#39;antoxine coquelucheuse, d&#39;hémagglutinine filamenteuse, de pertactine, de virus poliomyélitique inactivé type 1, type 2 et type 3 et de polyoside capsulaire d&#39;haemophilus influenzae type b (Infanrix - IPV/Hib)
PT824358E (pt) Vacinas acelulares contra a tosse convulsa e metodos para sua preparacao
DE69527202D1 (de) Proteinartige adjuvantien
FI913820A0 (fi) Traodlikt hemagglutinin fraon bordetella pertussis som baerarmolekyl foer konjugatvaccin.
UY26801A1 (es) Composición de vacuna
CY1110327T1 (el) DTPa ΕΜΒΟΛΙΑ ΒΛΕΝΝΟΓΟΝΟΥ
EP0952771A4 (en) SAPONIN COMPOSITIONS AND THEIR USE
GB9611501D0 (en) Vaccine compositions